Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRαβ+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801

8731 C-SIDE

Condition: BMT
Clinicaltrials.gov ID: NCT03619551

What is the goal of the study?

Busulfan exposure-finding for SCID with TCRαβ+/CD19+ depleted transplantation

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Lauri Burroughs
Study Team Member: Courtney Vandervlugt, cvanderv@fhcrc.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.